Article Text

PDF
CP-130 Analysis of the effectiveness and safety of infliximab in the treatment of psoriasis in a tertiary hospital
  1. A De Rivas-Bravo,
  2. A Maestro-Nombela,
  3. E De la Piedra-Ríos,
  4. A Martín-Alonso,
  5. A Sánchez-Guerrero
  1. Hospital Universitario Puerta de Hierro Majadahonda, Pharmacy, Majadahonda, Spain

Abstract

Background Psoriasis is an inflammatory skin disease characterised by increased cell signalling via cytokines and chemokines. A wide variety of treatment options are available including systemic biological treatments such as tumour necrosis factor antagonist infliximab.

Purpose To evaluate the effectiveness and safety of infliximab for the treatment of psoriasis in adults.

Material and methods Observational, retrospective study, from 2008 to 2014, in patients with psoriasis treated with infliximab in a tertiary hospital.

Data were obtained from the electronic medical history supported by Selene Clinical Station. Data collected were demographics, average treatment dose and duration, previous treatments, dose escalation and Psoriasis Area and Severity Index (PASI).

Results The study included 27 patients (66.7% males), mean age 49.7 years (25–88). The treatment protocol was infliximab 5 mg/kg infused as indicated in the Summary of Product Characteristics. The average dose and duration were 393.38 mg (300–585.22) and 4.074 years (1–6), respectively. Previous treatments used were 44.4% topical corticosteroids, 14.8% phototherapy, 18.5% ciclosporin, 44.4% methotrexate, 18.5% adalimumab and 7.4% etanercept.

Regarding treatment effectiveness, 7.4% of patients showed some resistance, 33.33% experienced some outbreaks and 59.2% became totally asymptomatic. The average PASI at baseline was 6.83 (0–50) and 1.9 (0–16) at the end. Intensification of treatment was indicated in 25.9% of patients who changed their infusion from every 8 to 6 weeks. Dose reduction was possible in 7.4% of patients with a dose of 4 mg/kg.

During treatment, 7.4% of patients had lower respiratory tract infections, 7.4% tonsillitis and 3.7% herpes zoster.

Conclusion

  • Most of the patients had a good response to treatment. Infliximab should be considered in patients who have failed to respond to, have a contraindication for, or are intolerant of, other systemic treatments.

  • Some of the patients developed infections. Risks and benefits of infliximab must be carefully considered prior initiating treatment in patients with chronic or recurrent infections.

References and/or Acknowledgements

  1. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf

References and/or AcknowledgementsNo conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.